ai3Bio Launches with $48 Million in Series A Funding to Reset the Immune System at Its Root
Platforms target and eliminate disease-causing Th17 cells in vivo, backed by lead investors UPMC Enterprises and Ziff Capital Partners
Press Releases
In The News